Welcome to our dedicated page for Lifeloc Technologies news (Ticker: LCTC), a resource for investors and traders seeking the latest updates and insights on Lifeloc Technologies stock.
Lifeloc Technologies, Inc. develops and manufactures breath alcohol testing devices and drug detection solutions for workplace, law enforcement, corrections and international customers. Company news commonly covers annual and quarterly operating results, revenue trends, gross margin, research and development spending, and capital actions tied to product development.
Updates also focus on the company’s SpinDetect™ Centrifugal Drug Analyzer, a compact, microfluidic-based drug screening platform under development from licensed SpinDx™ technology. Recurring announcements include product demonstrations, industry conference presentations, financing activity, and progress in portable alcohol detection and drug screening technologies.
Lifeloc Technologies (OTC:LCTC) reported first quarter 2026 net revenue of $2.294 million and a net loss of $153,000, or $(0.06) per diluted share. Revenue increased 1% year over year, while gross margin rose to 43% from 40%.
Research and development exceeded 18% of revenue, focused on the SpinDetect(TM) Centrifugal Drug Analyzer. Lifeloc completed SpinDetect disk production tooling, a key step before beta testing, and secured $500,000 in insider financing at 10.5% interest with interest-only payments in 2026.
Lifeloc Technologies (OTC:LCTC) reported 2025 revenue of $9.027M, up 6% from 2024, and a net loss of $2.470M (loss per diluted share $0.90) for year ended December 31, 2025. Management increased the deferred tax valuation allowance to $1.738M, a non-cash charge.
Gross margin stayed near 40.3%. Product progress includes certifications for L-series devices and a key SpinDetect™ disk production-mold milestone with first article molding expected in April 2026.
Lifeloc Technologies (OTC:LCTC) reported Q3 2025 results for the quarter ended Sept 30, 2025: Q3 net revenue $2.257M and a quarterly net loss $263k (EPS $(0.10)), versus Q3 2024 revenue $2.087M and loss $158k. Nine‑month 2025 net revenue was $6.754M with a YTD net loss $950k (EPS $(0.35)). Gross margin declined to 40.2% in Q3 (43.7% year‑ago) due to inflation and tariffs. Management cited high R&D spending to commercialize the SpinDetect™ centrifugal drug‑analyzer.
Operational highlights: lab validation of SpinDetect versus LCMS at ~10 ng/ml detection limits, signed beta‑testing agreement for an oral‑fluid THC analyzer, prototype demonstrations at trade shows, and a Form S‑4 filed Oct 15, 2025 for the proposed acquisition of Electronic Systems Technology (ELST).
Lifeloc Technologies (OTC:LCTC), a manufacturer of breath alcohol and drug detection devices, will present at the Emerging Growth Conference on September 25, 2025, at 2:20 PM EDT. CEO Dr. Wayne Willkomm will provide an operational overview and update on the SpinDetect™ centrifugal drug analyzer, the company's next-generation drug screening platform under development.
The interactive virtual presentation will include a Q&A session, with questions accepted both in advance and during the event. A recording will be available post-event on the Emerging Growth website and YouTube channel.
Lifeloc Technologies (OTCID:LCTC) has unveiled its innovative SpinDetect™ Centrifugal Drug Analyzer at the International Association of Chiefs of Police Conference in Chicago. The system processes oral fluid samples in under 15 minutes, delivering lab-grade analytical chemistry on a compact, automated disk platform.
The analyzer, based on licensed SpinDx™ microfluidic technology from Sandia Corporation, can detect multiple substances including delta-9-THC at 10 ng/ml, cocaine, fentanyl, amphetamine, methamphetamine, morphine, MDMA, and benzodiazepines. The company plans a phased commercial launch starting in 2026, initially focusing on THC detection disks, followed by expanded drug panels and additional sample types from blood and breath.
Lifeloc Technologies (OTCID:LCTC), a breath alcohol and drug testing device manufacturer, reported Q2 2025 financial results with net revenue of $2.219 million, down 7% year-over-year, and a net loss of $(394) thousand or $(0.14) per share.
The company maintained a gross margin of 41.7% while investing heavily in R&D ($623 thousand) for SpinDx development. Their strategic focus remains on the SpinDx technology platform for rapid drug detection, with commercial launch projected for early 2026. The platform has demonstrated effectiveness in detecting multiple drugs including THC, cocaine, and fentanyl.
Lifeloc has been approved for trading on the OTCID market tier, upgrading from OTC Pink Current Market as of July 1, 2025.
Lifeloc Technologies (OTC PINK:LCTC) reported its 2024 fiscal year results, showing an 8% revenue decline to $8.538 million from $9.330 million in 2023. The company posted a net loss of ($1.053) million, or ($0.41) per diluted share, compared to a net profit of $205.6 thousand in 2023. Gross margin decreased to 40.4% from 43.3%.
The decline was attributed to normalized demand following 2023's pent-up demand and inflation's impact on customer budgets. The company's L-series devices (LX9 and LT7) are gaining market penetration with features like smartphone pairing and local language customization.
Lifeloc is heavily investing in SpinDx technology development, a 'Lab on a Disk' platform for rapid drug detection. Beta testing of the SpinDx saliva testing system for THC detection is planned for Q2 2025, with commercial launch projected for early 2026. To support development, the company secured a $750,000 debenture in late 2024 and an additional $75,000 in Q1 2025.
Lifeloc Technologies (OTC PINK:LCTC) has secured a $750,000 financing through a subordinated debenture agreement with Diamond Bridge Capital, LP. The deal includes a warrant to purchase 62,500 shares at $4.50 per share and carries an 8.25% annual interest rate, maturing December 31, 2030.
The funding will support growth initiatives and R&D efforts, particularly the commercialization of SpinDx technology, which aims to revolutionize drug testing by providing quick, local results within minutes at approximately $25 per test, compared to current lab testing costs of $100-$300 with longer wait times.
The company plans to launch SpinDx in Q4 2025, with ongoing efforts to reduce the prototype reader size by 25%. Lifeloc has confirmed the technology's accuracy through in-house testing with samples from Anschutz Medical Center and plans to establish beta test sites for further validation.
Lifeloc Technologies (LCTC) reported Q3 2024 financial results with net revenue of $2.087 million, down 23% from $2.696 million in Q3 2023. The company posted a quarterly net loss of $(158) thousand, or $(0.06) per share, compared to a profit of $110 thousand, or $0.04 per share in Q3 2023. Gross margin improved to 43.7% from 41.5% year-over-year. The company secured a $750,000 line of credit and raised $798,000 through a private placement of 210,000 shares at $3.80 per share. Lifeloc plans to launch its SpinDx saliva testing system for drug detection in late 2025.